Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Now, Cigna’s Express Scripts is following suit ...

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Sept 10 (Reuters) - UnitedHealth Group (UNH.N), opens new tab said on Tuesday it will remove AbbVie’s (ABBV.N), opens new tab blockbuster rheumatoid arthritis drug Humira from some of its lists of ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie 's Humira are plummeting as the once-top-selling drug fights ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...